Physician profile
Frederick Schnell
NPI 1114954310
$66,746.51
in general payments reported to CMS, 2019-2025
29 companies · $1,958 in 2025
The $1,958 reported for 2025 was more than what 94% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23K · 2020: $2,896 · 2021: $11K · 2022: $14K · 2023: $11K · 2024: $3,078 · 2025: $1,958.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $14K · Food and Beverage: $1,057 · Travel and Lodging: $582.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $14,237.00 |
| Food and Beverage | $1,057.29 |
| Travel and Lodging | $582.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $13,047.40 | 2020-2024 | Imdelltra (Amg 757), Kyprolis, Blincyto |
| Regeneron Pharmaceuticals, INC. | $12,135.87 | 2023-2025 | Libtayo, Lynozyfic |
| Celgene Corporation | $9,426.23 | 2019-2020 | |
| Abbvie INC. | $6,047.20 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $6,030.90 | 2019 | |
| Pfizer INC. | $5,600.00 | 2021 | |
| Merck Sharp & Dohme LLC | $5,119.29 | 2019-2020 | |
| Glaxosmithkline, LLC. | $2,600.00 | 2020 | |
| Fresenius Kabi USA, LLC | $2,436.00 | 2021-2022 | |
| Janssen Biotech, INC. | $1,754.67 | 2019-2023 | Darzalex |
| Astrazeneca Pharmaceuticals Lp | $1,123.64 | 2019-2020 | |
| Astellas Pharma US INC | $345.03 | 2019-2024 | Xtandi |
| Eisai INC. | $267.97 | 2019-2024 | |
| Organon LLC | $193.32 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $150.01 | 2023-2025 | Iclusig |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardinal Health 110 LLC | $150.00 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $82.23 | 2020-2023 | Opdivo, Pomalyst |
| Beigene USA, INC. | $54.41 | 2022-2024 | Brukinsa |
| Genentech USA, INC. | $32.15 | 2021-2023 | Venclexta |
| Daiichi Sankyo INC. | $29.43 | 2025 | Datroway |
| Gilead Sciences, INC. | $22.67 | 2025 | Trodelvy |
| Genzyme Corporation | $19.44 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $17.55 | 2020 | |
| Clovis Oncology, INC. | $16.57 | 2019 | |
| Stemline Therapeutics INC. | $15.69 | 2023 | Orserdu |
| Coherus Oncology, INC. | $14.55 | 2022 | |
| Seagen INC. | $14.29 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Schnell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.